Xiuying Hu
Cross Cancer Institute
4 Papers
Xiuying Hu is an academic researcher from Cross Cancer Institute. The author has contributed to research in topics: Cancer research & Biology. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle.
Wilson Roa,Xiaojing Zhang,Linghong Guo,Andrew R.E. Shaw,Xiuying Hu,Yeping Xiong,Sunil Gulavita,Samir Patel,Xuejun Sun,Jie Chen,Ronald B. Moore,James Xing,James Xing +12 more
TL;DR: Glu-GNPs trigger activation of the CDK kinases leading to cell cycle acceleration in the G0/G1 phase and accumulation in theG2/M phase and this activation is accompanied by a striking sensitization to ionizing radiation, which may have clinical implications.
319
From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases
Yumeng Zhu,Ping Xu,Xu-Hong Huang,Wen Shuai,L. Liu,Shuai Zhang,Rui Zhao,Xiuying Hu,Guangqing Wang +8 more
TL;DR: This study aims to provide a novel idea for targeted therapy of neurodegenerative diseases through targeting NAMPT, which is specifically highly expressed in the hippocampus by inducing the biosynthesis of NAD in neural stem cells/progenitor cells.
Nuclear factor Nrf2 promotes glycosidase OGG1 expression by activating the AKT pathway to enhance leukemia cell resistance to cytarabine
Qin Shang,Chengyun Pan,Xi Zhang,Tonghua Yang,Tianzhen Hu,Lin Zheng,Shuyun Cao,Cheng Feng,Xiuying Hu,Xiao Chai,Ji-Shi Wang,Qin Fang +11 more
TL;DR: Wang et al. as mentioned in this paper found that upregulation of nuclear factor E2-related factor 2 (Nrf2) in leukemia cells by lentivirus transfection could decrease the sensitivity of leukemia cells to cytarabine and decrease OGG1 expression.